The Valley Desk

ArticleCancersPublished

Outcomes with Single Tremelimumab Regular Interval Durvalumab (STRIDE) for Unresectable Hepatocellular Carcinoma in the US Veterans Administration

Read the publication ↗ Open access copy ↗

Regional connection

Verified Author affiliations on the Europe PMC record name Perelman School of Medicine, Philadelphia VA Medical Center, Thomas Jefferson University, University of Pennsylvania. Affiliation source

Publication record

Type
Article
Venue
Cancers
Published
Subject terms
Safety; Survival; Carcinoma; Hepatocellular; Therapeutics
PubMed ID
41976308
PubMed Central ID
PMC13072021
Open access
Yes, open
Added to directory
Source checked

Report a correction or request removal